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Prospective Evaluation of the Prognostic
Implications of Improved Assay Performance
With a Sensitive Assay for Cardiac Troponin I
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Anthony Dalby, MD,‡ Jindrich Spinar, MD,§ Sabina A. Murphy, MPH,* Peter Jarolim, MD, PHD,†
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Boston, Massachusetts; Johannesburg, South Africa; and Pekarska, Czech Republic
Objectives The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac tropo-
nin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS).
Background Recent enhancements in troponin assays have enabled resolution of the 99th percentile reference limit at pro-
gressively lower concentrations. However, the clinical significance of low-level increases with sensitive assays is
still debated.
Methods We measured cTnI using a sensitive assay (TnI-Ultra, Siemens Healthcare Diagnostics, Deerfield, Illinois) at base-
line in 4,513 patients with non–ST-segment elevation ACS randomly assigned to ranolazine or placebo. We ap-
plied decision limits at the 99th percentile reference limit (0.04 g/l), the cut point of the predecessor assay
(0.1 g/l), and 1 equivalent to elevation of creatine kinase–myocardial band (1.5 ng/ml).
Results Patients with baseline cTnI 0.04 g/l (n  2,924) were at higher risk of death/myocardial infarction (MI)
at 30 days than were patients with a negative cTnI (6.1% vs. 2.0%, p  0.001). After adjusting for the TIMI
(Thrombolysis In Myocardial Infarction) risk score, cTnI 0.04 g/l was associated with a 3-fold (95% confi-
dence interval: 2.0 to 4.4, p  0.001) higher risk of death/MI at 30 days. Moreover, patients with low-level
increases (0.04 g/l to 0.1 g/l), were at significantly higher risk of death/MI at 30 days (5.0% vs. 2.0%,
p  0.001) and death at 12 months (6.4% vs. 2.4%, p  0.005) than were patients with cTnI 0.04 g/l.
Conclusions Low-level increases in cTnI using a sensitive assay identify patients at higher risk of death or MI. These findings
support current American College of Cardiology/American Heart Association recommendations defining MI, and
the incremental value of newer, more sensitive assays in identifying high-risk patients with ACS. (J Am Coll
Cardiol 2010;55:2118–24) © 2010 by the American College of Cardiology Foundation













Sardiac troponin (cTn) is the preferred cardiac biomarker of
ecrosis for diagnosis and risk assessment in patients pre-
enting with suspected acute coronary syndromes (ACS)
1–3). More than 30 studies have demonstrated a strong
elationship between cTn and prognosis independent of
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May 11, 2010:2118–24 Prognostic Performance of TnI-Ultraoward lower concentrations. Professional guidelines have rec-
mmended a diagnostic limit based on the 99th percentile of a
eference population instead of higher cut points defined by
omparison to creatine kinase-myocardial band (CK-MB)
3,7). At the same time, enhancements to the analytic perfor-
ance of commercially available assays for cTn have enabled
eliable detection of the 99th percentile at lower concentrations
f cTn (2). Recently, several such sensitive assays for cTn were
hown to improve significantly the overall diagnostic accuracy
ver prior generation assays (8,9). Nevertheless, the accompa-
ying substantial increase in the proportion of patients pre-
enting with chest pain who are found to have elevated
roponin continues to raise doubt for many practitioners as to
he clinical significance of such low-level increases in cTn
dentified by these newer, more sensitive assays and the
ppropriateness of the 99th percentile cut point (10–13).
herefore, we investigated the prognostic performance of 1
uch sensitive commercial assay for cTnI (8,9) at the 99th
ercentile decision limit in a robustly sized population with
uspected ACS, with a specific interest in subjects with
ow-level increases.
ethods
atient population. In the MERLIN–TIMI 36 (Meta-
olic Efficiency With Ranolazine for Less Ischemia in Non-ST
levation Acute Coronary–Thrombolysis In Myocardial Infarc-
ion 36) trial, 6,560 patients with non–ST-segment eleva-
ion acute coronary syndrome (NSTE-ACS) were enrolled
etween October 2004 and May 2006. They were assigned
andomly to treatment with either ranolazine or placebo in
1:1 ratio and followed up for a median of 348 days (14).
he median time from symptom onset to randomization
as 23 h (25th, 75th percentiles: 13 h, 24 h). The study
esign and primary results have been published previously
15). Eligible patients were 18 years of age or older, had
ymptoms consistent with myocardial ischemia at rest, and
ad at least 1 of the following indicators of moderate to high
isk of death or recurrent ischemic events: elevated biomar-
er of necrosis, ST-segment depression of at least 0.1 mV,
iabetes mellitus, or an intermediate or high (3) TIMI risk
core for unstable angina/non–ST-segment elevation MI.
ajor exclusion criteria included cardiogenic shock, persis-
ent ST-segment elevation, successful revascularization of
he culprit lesion before randomization, and life expectancy
12 months. The MERLIN–TIMI 36 trial, including this
ubstudy, was approved by the relevant institutional review
oards at all participating centers. Written informed con-
ent was obtained from all patients.
roponin testing. Baseline blood samples were to be col-
ected in all patients at all sites in countries participating in the
iomarker substudy. Serum samples were isolated on site and
tored at 20°C or colder for 6 weeks. Samples were
ubsequently shipped frozen to the TIMI Clinical Trials
aboratory (Boston, Massachusetts) where they were stored
t 80°C or colder. Cardiac troponin I was measured in matches using the TnI-Ultra as-
ay (ADVIA Centaur, Siemens
ealthcare Diagnostics, Deerfield,
llinois) by personnel blinded to
reatment allocation and clinical
vents. This assay is a sandwich
mmunoassay using monoclonal
apture antibodies directed against
he stable central region of the TnI
olecule and 1 polyclonal detect-
ng antibody (10). The lower limit
f detection is 0.006 g/l. The
9th percentile reference limit has
een established at 0.04 g/l (10).
he total imprecision is 10% at a
oncentration of 0.03 g/l.
nd points. Commensurate with previous studies evaluat-
ng the prognostic performance of troponin, the primary end
oint for this analysis was death or myocardial infarction (MI).
he primary efficacy end point for the MERLIN–TIMI 36
rial was a composite of cardiovascular death, MI, or
ecurrent ischemia through the end of the trial. The
efinitions for each component of the end point have been
escribed previously (15). Each element was adjudicated by
n independent clinical end points committee, blinded to
reatment allocation.
tatistical methods. Baseline characteristics were com-
ared using the chi-square test for categorical variables and
he Wilcoxon rank-sum test for continuous ones. We
nalyzed the prognostic implications of this assay using
ontemporary guidelines (99th percentile cut point at 0.04
g/l), as well as divided into 3 strata defined by the 99th
ercentile (0.04 g/l), the cut point defined for the prior
eneration assay (0.1 g/l), and a cut point (1.5 g/l)
quivalent to that of CK-MB (3,7). An exploratory analysis
as performed examining the cohort with cTnI values
elow the 99th percentile (0.04 g/l) and above the lower
imit of detection (0.006 g/l). The assessment of the
elationship between cTnI and outcome was performed
sing Cox regression. Adjusted analyses were performed
ncluding all elements of a well-validated risk model in ACS
TIMI risk score) (16). There was no interaction with the
andomized therapy, and therefore, treatment allocation was
ot included in the model. Event rates presented are
roportions at 30 days, and Kaplan-Meier estimates of the
umulative incidence at 12 months. The increased discrim-
native value of cTnI was further examined with the method
escribed by Pencina et al. (17) to determine the net
eclassification improvement and the integrated discrimina-
ion improvement, which evaluates the change in the
stimated risk as a continuous variable. For net reclassifica-
ion improvement, patients were separated into risk tertiles
ccording to a clinical risk score using the TIMI risk score,
reatinine clearance 60 ml/min, and a history of heart
ailure, and reclassification was determined by the same
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
cTn  cardiac troponin
HR  hazard ratio
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
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Prognostic Performance of TnI-Ultra May 11, 2010:2118–24ere performed using STATA version 9.2 (StataCorp LP,
ollege Station, Texas).
esults
aseline characteristics. Baseline samples were available
or analysis in 4,513 of the 6,560 patients enrolled in the
linical trial. Their baseline characteristics are listed in Table 1.
he baseline concentration of cTnI was 0.04 g/l in 65%
f patients. Patients with baseline cTnI 0.04 g/l were
lder and more frequently male, and current smokers. They
ere also more likely to have presented later (24 h vs. 20 h)
nd to have high-risk findings including ST-segment de-
ression or a TIMI risk score for NSTE-ACS 4. Patients
ith a cTnI 0.04 g/l were more likely to receive
hienopyridines and glycoprotein IIb/IIIa inhibitors, and to
ndergo coronary angiography. The randomized treatment
ranolazine or placebo) was well balanced among patients
ith and without cTnI 0.04 g/l.
roponin concentration and prognosis. 99TH PERCENTILE
ECISION LIMIT. At 30 days, compared to patients with
TnI 0.04 g/l, patients with baseline cTnI 0.04 g/l
ad significantly higher rates of death (2.1% vs. 0.5%, p 
.0001), and death or MI (6.1% vs. 2.0%, p  0.0001). The
igher risk of adverse outcomes associated with cTnI0.04
g/l persisted at 12 months for both death (6.6% vs. 2.4%,
 0.0001), and death or MI (14.1% vs. 5.6%, p 0.0001)













Previous PCI or CABG
Creatinine clearance 60 ml/min
Presentation
TIMI risk score 4, %
ST-segment depression 0.1 mV, %
Time from symptom onset, h, median (IQR)
Treatment, %
Coronary angiography during index hospitalization
Thienopyridine during index hospitalization
GPIIb/IIIa inhibitor during index hospitalization
Randomization group (ranolazine)
CABG coronary artery bypass graft surgery; CHF congestive heart f
MI  myocardial infarction; PCI  percutaneous coronary interventionFig. 1). Patients with an elevated baseline cTnI were also at 0igher risk of the primary composite end point for the trial
f cardiovascular death, MI, or recurrent ischemia at 30 days
9.9% vs. 4.4%, p  0.0001) and at 12 months (21.7% vs.
3.6%, p  0.0001) (15).
When adjusted for elements of the TIMI risk score for
STE-ACS including age, multiple coronary risk factors,
nown coronary disease, recent aspirin use, repeated epi-
odes of rest-angina, and ST-segment deviation, patients
ith increased cTnI 0.04 g/l at presentation were at
-fold higher risk of death when compared to patients with
TnI 0.04 g/l (adjusted hazard ratio [HR]: 3.0, 95%
onfidence interval [CI]: 1.4 to 6.4) and death or MI
adjusted HR: 3.0, 95% CI: 2.0 to 4.4) at 30 days. Similarly,
t 12 months, the significant association between cTnI and
utcome remained apparent with respect to death (adjusted
R: 2.4, 95% CI: 1.8 to 3.5) and death or MI (adjusted
R: 2.7, 95% CI: 2.1 to 3.4) (Table 2). In addition, adding
TnI to the clinical model resulted in a significant net
eclassification improvement of 0.405 (p  0.0001) and
n integrated discrimination improvement (p  0.0001) for
eath or MI. There was no evidence for an interaction
etween the baseline cTnI result and the efficacy of rano-
azine (p value for interaction  0.76).
OW-LEVEL ELEVATION. Among patients with cTnI0.04





(n  2,924) p Value
63 65  0.001
43 31  0.001
97 97 0.704
(73–93) 81 (72–92) 0.008
37 30  0.001
20 28  0.001
84 67  0.001
77 63  0.001
44 31  0.001
29 16  0.001
34 22  0.001
18 21 0.004
13 26  0.001
26 41  0.001
(10.2–30.2) 24 (14.4–35.1)  0.001
40 63  0.001
47 73  0.001
4 19  0.001
49 50 0.507
TnI cardiac troponin I; GP glycoprotein; IQR interquartile range;
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May 11, 2010:2118–24 Prognostic Performance of TnI-Ultraelow the cut point (1.5 g/l), equivalent to an abnormal
ncrease in CK-MB. When stratified by these specified cut
oints (0.04 to 0.1, 0.1 to 1.5, and 1.5) and compared
o patients with cTnI 0.04 g/l, patients with low-level
ncreases (0.04 to 0.1) had a significantly higher incidence
f death or MI both at 30 days and at 12 months (Fig. 2).
atients with cTnI between 0.04 g/l and 0.1 g/l had a more
han 2-fold higher risk of adverse outcomes at 30 days when
ompared to patients with cTnI0.04g/l (death or MI 5.0%
s. 2.0%, p  0.001; death 1.3% vs. 0.5%, p  0.12). At 12
Figure 1 Risk of Death or MI by Baseline cTnI Result
Kaplan-Meier estimated cumulative incidence of (A) death or myocardial infarc-
tion (MI) and (B) death stratified by baseline cardiac troponin I (cTnI) concen-
tration using the 99th percentile reference limit (0.04 g/l [cTnI 0.04 g/l,
n  2,924; cTnI 0.04 g/l, n  1,589]).
Outcomes Stratified by Baseline cTnI at the 99tTable 2 Outcomes Stratified by Baseline cT
Outcome cTnI <0.04 g/l
30 days
n 1,589
Death (%) 8 (0.5)
Death or MI (%) 31 (2.0)
Primary end point (%) 70 (4.4)
12 months
Death (%) 39 (2.4)
Death or MI (%) 86 (5.6)
Primary end point (%) 218 (13.6)
*Adjusted for all elements of TIMI risk score (age, multiple coronary ris
and ST-segment deviation).
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tabonths, there was a similar increase in the incidence of
ecurrent events in patients with low-level cTnI elevations
ompared to patients with no detectable cTnI (death 6.4% vs.
.4%, p  0.005). Additional analysis of the group with cTnI
0.04 g/l showed that patients with cTnI 0.006 and
0.04 were at numerically but not significantly higher risk of
eath or MI at 12 months than were patients with cTnI
0.006 (5.8% vs. 4.0%, p  0.42).
When adjusted for elements of the TIMI risk score for
STE-ACS, patients with low-level cTnI elevation (0.04
g/l to0.10 g/l) were at increased risk of death (adjusted
R: 1.8, 95% CI: 1.05 to 3.21) and death or MI (adjusted
R: 2.14, 95% CI: 1.48 to 3.10) at 12 months (Fig. 3).
iscussion
he recommended clinical decision limits for cTn for
linical practice have moved toward lower concentrations
13). Newer generations of current commercial assays have
nabled measurement of cTn at concentrations not reliably
etected with prior generations, improving overall diagnos-
ic accuracy (13) but fostering lingering uncertainty for
any practitioners as to the clinical relevance of very low
evel increases in cTn (13). In this prospectively designed
valuation of 1 such widely employed sensitive assay for
TnI in 4,500 subjects with ACS, we demonstrated
xcellent prognostic performance at the 99th percentile cut
oint and found, in particular, that elevated cTnI in the
owest range (10% of the population) identified with this
ensitive assay was indeed associated with an increased
hort- and intermediate-term risk of death and recurrent
ajor cardiovascular events. This assessment of the clinical
ignificance of low level elevations of cTnI, using the
nI-Ultra assay as an example, confirms the pattern of
ustained prognostic relevance in patients with chest symp-
oms consistent with ACS as assays have evolved toward
ore sensitive current generations.
valuation of low-level increases in cardiac troponin. The
ntroduction of cardiac troponin more than a decade ago as
more sensitive tool for detection of myocardial injury than
rcentile Cut Pointthe 99th Percentile Cut Point
I >0.04 g/l
Adjusted HR*
(95% CI) p Value
2,924
60 (2.1) 3.0 (1.4–6.4) 0.004
178 (6.1) 3.0 (2.0–4.4)  0.001
289 (9.9) 2.2 (1.7–2.9)  0.001
198 (6.6) 2.4 (1.8–3.5)  0.0001
413 (14.1) 2.7 (2.1–3.4)  0.0001
628 (21.7) 1.6 (1.4–4.8)  0.0001
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Prognostic Performance of TnI-Ultra May 11, 2010:2118–24K-MB raised appropriate questions regarding the clinical
eaning of myocardial necrosis detected with this new,
ore sensitive biomarker. These questions were addressed
y outcomes studies that firmly established that MIs de-
ected with troponin but not CK-MB were associated with
substantial risk of death or recurrent ischemic events. For
xample, in a study of 359 patients presenting with unstable
ngina and negative serial CK-MB values, patients with
TnI 0.1 ng/ml were at significantly increased risk of
eath or MI at both 48 h and 14 days (18). Subsequently,
he move to lower decision limits for troponin raised the
ame questions regarding the clinical significance of quan-
itatively small increases in cTn above the 99th percentile.
gain, this issue was resolved by consistent findings from
everal prospective studies nested in clinical trials as well as
n community-based populations establishing the prognos-
ic relevance of such “low-level” increases in cTn using prior
eneration assays that were less sensitive than in those used
urrently (9). For example, the relationship of outcomes and
egree of cTnI elevation was evaluated by Kontos et al. (19)
n a study of 4,123 patients presenting with suspected
Figure 2 Kaplan-Meier Estimated Event Rates for Death or MI
Kaplan-Meier estimated event rates for death or myocardial infarction (MI) at
(A) 30 days and (B) 12 months by strata of baseline cardiac troponin I (cTnI).
Patients who had low-level elevation of cTnI (0.04 g/l to 0.1 g/l) were at
significantly increased risk of death or MI compared with patients who did not
have elevated cTnI. p  0.001.STE-ACS in a community-based population. Patientsho had a peak cTnI value greater than the lower limit of
etection and 99th percentile as well as those with a peak
TnI 99th percentile but less than the manufacturer’s
uggested upper reference limit had significantly increased
isk of death at 30 days and 6 months compared with
atients who had nondetectable cTnI (19). Now, the
mergence of commercial assays with improved analytical
erformance, including approximately 10-fold higher sen-
itivity than prior assays, has enabled the reliable detection
f even lower concentrations of cTn and provided enhanced
iagnostic accuracy (8,9,13). Nevertheless, this progress
gain requires the medical community to critically assess the
rognostic implications of cTn detected with newer assays.
To address this issue, we studied a current-generation
ensitive assay (TnI-Ultra). In prior work with this assay,
pple et al. (11) measured cTnI at 2 time points in 371
atients with suspected ACS who were followed up for 60
ays and found that results99th percentile (0.04 g/l to
Figure 3 Adjusted HR for Death and Death or MI
Adjusted hazard ratio (HR) for death and death or myocardial infarction (MI) at
(A) 30 days and (B) 12 months stratified by baseline cardiac troponin I (cTnI).
After adjusting for established clinical predictors of outcome, patients who had
low-level elevation of cTnI were consistently at higher risk of recurrent cardio-
vascular events compared with patients who had cTnI 0.04 g/l. *Adjusting
for all elements of TIMI risk score (age, multiple coronary risk factors, known
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May 11, 2010:2118–24 Prognostic Performance of TnI-Ultra.10 g/l) were predictive of the risk of death or first cardiac
vent (MI or revascularization) with an adjusted HR of 8.9
95% CI: 2.4 to 34). Those with TnI between 0.006 g/l
nd 0.04 g/l (n  174) were also at significantly increased
isk of the composite end point (adjusted HR: 3.9, 95% CI:
.2 to 13). Notably, more than one-third of the end point
vents were revascularization procedures that appeared to
ccur during the index hospitalization, and the study overall
as not powered to examine death or MI (11).
In our study of 4,513 patients with an average follow-up
f 1 year, we found that this current-generation assay
dentified patients with low-level increases in cTnI (0.04
g/l to 0.10 g/l) who were at more than 2-fold higher risk
f death and death or new MI at 30 days and at 1 year. Our
ndings provide strong evidence for the enhanced prognos-
ic performance of more sensitive current-generation assays
or cTn in patients with a clinical syndrome consistent with
CS, and establish the clinical relevance of such low-level
ncreases in cTnI using a current-generation assay at the
ontemporary cut point (99th percentile) recommended by
he universal definition of MI (7). This finding was inde-
endent of other routinely used clinical tools for risk
ssessment in ACS, including electrocardiographic findings,
rior coronary artery disease, and the tempo of chest
ymptoms. In contrast to the study by Apple et al. (11), in
ur study, we did not find a significant increase in risk in
hose patients with a detectable cTnI below the 99th
ercentile (i.e., between 0.006 g/l and 0.04 g/l).
uture directions. This trend toward the clinical applica-
ion of even lower concentrations of cardiac troponin is
ikely to continue. Other sensitive assays for cTn are
ommercially available (9,13), and at the same time, re-
earch assays for cTn are emerging that provide sensitivity
nd precision that is increased an order of magnitude over
he present sensitive commercial assay, including the
urrently used cTnI Ultra assay employed in this study
20–22). As an example, using the single-photon fluores-
ence detection method, a 10% coefficient of variation was
eported at 0.0018 g/l (23). This emerging group of assays
ffers the possibility of fully characterizing the distribution
f cTn in the healthy population, as well as detecting very
mall changes in cTn concentration over time that may
acilitate discrimination of acute myocardial injury from
hronic causes of elevated circulating cTn, thereby improv-
ng the very early detection of patients with ACS (24,25).
oreover, preliminary investigation of cut points below the
9th percentile has revealed an association between in-
reases in cTn higher than the limit of detection and adverse
ardiovascular outcomes (26,27). Implementation of cut
oints below the 99th percentile may be particularly relevant
or emerging applications for cTn, such as risk stratification
n patients with stable coronary artery disease or identifica-
ion of subclinical structural heart disease in patients at risk
27–29).
These trends toward new uses of more sensitive assays for
Tn are associated with important challenges that must beavigated to guide any new clinical applications (24). In
articular, consensus with regard to what defines an appro-
riate “normal reference population” has not been reached.
lso, it will be necessary to re-evaluate the possible impact
f biological variability and assay interference from nonspe-
ific antibody binding that have not been meaningful with
ssays available to date (30). Adequately powered clinical
tudies are needed to assess whether the therapeutic impli-
ations of low concentrations of cTn using a high-sensitivity
ssay are the same as those established for current commer-
ial assays. Although use of lower cut points will facilitate
dentification of additional patients at risk for recurrent
schemic events, it is important to determine whether this
isk may be modified by altering therapy, as compared with
atients who have normal troponin results.
tudy limitations. This study was limited to patients
elected for participation in a clinical trial who presented
ith suspected ACS. As such, these results do not address
he question of prognostic significance in the broader group
f patients presenting with nontraumatic chest pain, includ-
ng patients with symptoms atypical for myocardial ischemia
r presenting with other acute illnesses. In addition, the
andscape of technical advances in assays for troponin is
hanging rapidly. Although our results provide an important
roof-of-principle that is likely to apply qualitatively to
ther assays with similar sensitivity, it is not possible to
onfirm the prognostic performance of other assays without
irect investigation, including the next generation of re-
earch assays presently under study (13). Samples were
tored in liquid nitrogen to maximize sample stability; in
ddition, any degradation of troponin during long-term
torage would introduce random noise to our analysis and
ould be expected to have resulted in our underestimating
he strength of the risk relationship with outcome.
onclusions
e found that low-level increases in cTnI, as detected by a
urrent-generation sensitive commercial assay, in patients
resenting with suspected ACS were associated with an
dverse prognosis over the short and long term. These
esults indicate the clinical relevance of cTn detected with
ewer sensitive assays for troponin. In addition, our findings
upport current guidelines for use of the 99th percentile cut
oint established by the universal definition of MI (7).
eprint requests and correspondence: Dr. Marc P. Bonaca,
IMI Study Group, Cardiovascular Division, Brigham and
omen’s Hospital, 75 Francis Street, Boston, Massachusetts
2115. E-mail: mbonaca@partners.org.
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